Boston Scientific Announces Strong Third Quarter 2025 Results

Details

The company reported GAAP net income of $755 million, or $0.51 per share, and adjusted EPS of $0.75. The company also provided guidance for the full year 2025, expecting net sales growth of approximately 20% on a reported basis and 15.5% on an organic basis. Boston Scientific also furnished financial statements and exhibits, including the third quarter 2025 earnings release.

Items reported

About Boston Scientific Corporation

Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.